marc de garidel thoron

About marc de garidel thoron

Marc de Garidel is a seasoned French business leader with deep experience in pharmaceuticals, biotechnology, and listed-company governance. He joined Ipsen in November 2010 as Chairman and Chief Executive Officer, a role he held until July 2016. During that period, he helped strengthen the group’s strategic positioning, operational discipline, and international profile. Ipsen has continued to identify him as Chairman of the Board of Directors in its corporate governance materials, underscoring his long-standing role in overseeing the company at board level and contributing to the supervision of a major publicly listed life-sciences business. Before joining Ipsen, he built a substantial career at Eli Lilly and then at Amgen, where he worked from 1995 to 2010 in progressively senior roles in the United States and Europe. His responsibilities included finance, treasury, corporate control, accounting leadership, and regional general management. This background gave him a broad command of corporate finance, performance management, commercial execution, and cross-border organization leadership. It also explains why he is often associated with strong financial rigor and a highly structured approach to value creation in regulated healthcare businesses. In April 2023, Abivax announced his appointment as Chief Executive Officer and Interim Board Chair, effective 5 May 2023. Abivax’s leadership materials later confirmed that he took up his duties in May 2023. Since then, he has been at the helm of a clinical-stage biotechnology company focused on immune-mediated inflammatory diseases, including the advancement of obefazimod, the company’s lead drug candidate. His appointment reflects a profile well suited to high-stakes biotech leadership: combining operational credibility, capital markets experience, boardroom expertise, and the ability to guide a company through late-stage development and strategic milestones. Overall, Marc de Garidel stands out as a governance-focused executive with a strong track record in large-cap pharmaceuticals and biotechnology. He has led companies, chaired boards, and navigated complex strategic transitions, making him a notable figure in the French and international life-sciences landscape.